Currently, clinical interventions for IBD are primarily based on the management of persisting inflammation through targeting of TNF-α, or the inhibition of IL-12 and/or IL-23 cytokines through p19 or p40-subunit specific antibodies, or the use of steroids to dampen the overall inflammatory response (221). Here, TNF is linked to inflammatory bowel disease.